SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The primary objective of the study is to assess the activity of fulvestrant in postmenopausal women with advanced breast cancer failing treatment with non-steroidal or steroidal aromatase inhibitors by estimating the Clinical Benefit Rate

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Aromatase Inhibitors; Estradiol; Fulvestrant

Criteria

Inclusion Criteria:

• Histological/cytological confirmation of breast cancer

• progression under treatment with an aromatase inhibitor

• At least one measurable or non-measurable lesion

Exclusion Criteria:

• Prior treatment for breast cancer with more than 2 different hormonal agents

• More than 1 chemotherapy for advanced disease

• Presence of life-threatening metastatic visceral disease